↓ Skip to main content

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

Overview of attention for article published in Systematic Reviews, December 2019
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
22 Mendeley